Can an arthritis drug keep HIV in check without daily pills?
NCT ID NCT07209267
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether baricitinib, an FDA-approved drug for other conditions, can keep HIV under control after participants stop their usual antiretroviral therapy (ART). Twenty people with well-controlled HIV will take baricitinib alongside ART for 26 weeks, then continue baricitinib alone for up to 24 weeks. The goal is to see if baricitinib delays viral rebound and reduces the need to restart ART.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Gavegnano's Laboratory
Atlanta, Georgia, 30322, United States
-
Grady Infectious Diseases Clinic (Ponce Center)
Atlanta, Georgia, 30308, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Can a new strategy break the cycle of HIV care dropout?
- Faith-Based therapy aims to heal trauma in young women
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women